Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [60988d6f-de9a-4ea4-b911-0c0e1d1790f4] => Array ( [runtime-id] => 60988d6f-de9a-4ea4-b911-0c0e1d1790f4 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [74de34f0-5a9e-4c22-a41f-a03a673375a0] => Array ( [runtime-id] => 74de34f0-5a9e-4c22-a41f-a03a673375a0 [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;e6e44ffaca317891d15fac120332bb721c07526c ) ) ) 1naresh2naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [60988d6f-de9a-4ea4-b911-0c0e1d1790f4] => Array
        (
            [runtime-id] => 60988d6f-de9a-4ea4-b911-0c0e1d1790f4
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [74de34f0-5a9e-4c22-a41f-a03a673375a0] => Array
                        (
                            [runtime-id] => 74de34f0-5a9e-4c22-a41f-a03a673375a0
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;e6e44ffaca317891d15fac120332bb721c07526c
                )

        )

)

Table 2: Visibility scores for the clinical study
Visibility Score
−2 −1 0 +1 +2
Total scores (n = 120) n = 9 n = 10 n = 34 n = 25 n = 42
(2 readers) (7.5%) (8.3%) (28.3%) (20.8%) (35.0%)
Iodine concentration 
    66 mg/mL (n = 34) n = 7 n = 5 n = 15 n = 6 n = 1
(20.6%) (14.7%) (44.1%) (17.6%) (2.9%)
    100 mg/mL (n = 32) n = 2 n = 5 n = 9 n = 10 n = 6
(6.3%) (15.6%) (28.1%) (31.3%) (18.8%)
    133 mg/mL (n = 26) n = 0 n = 0 n = 2 n = 3 n = 21
(0%) (0%) (7.7%) (11.5%) (80.8%)
    150 mg/mL (n = 28) n = 0 n = 0 n = 8 n = 6 n = 14
(0%) (0%) (28.6%) (21.4%) (50.0%)
Injection technique 
    ILESI (n = 64) n = 0 n = 3 n = 14 n = 17 n = 30
(0%) (4.7%) (21.9%) (26.6%) (46.9%)
    TFESI (n = 56) n = 9 n = 7 n = 20 n = 8 n = 12
(16.1%) (12.5%) (35.7%) (14.3%) (21.4%)

	Visibility Score
	−2	−1	0	+1	+2
Total scores (n = 120)	n = 9	n = 10	n = 34	n = 25	n = 42
(2 readers)	(7.5%)	(8.3%)	(28.3%)	(20.8%)	(35.0%)
Iodine concentration
66 mg/mL (n = 34)	n = 7	n = 5	n = 15	n = 6	n = 1
	(20.6%)	(14.7%)	(44.1%)	(17.6%)	(2.9%)
100 mg/mL (n = 32)	n = 2	n = 5	n = 9	n = 10	n = 6
	(6.3%)	(15.6%)	(28.1%)	(31.3%)	(18.8%)
133 mg/mL (n = 26)	n = 0	n = 0	n = 2	n = 3	n = 21
	(0%)	(0%)	(7.7%)	(11.5%)	(80.8%)
150 mg/mL (n = 28)	n = 0	n = 0	n = 8	n = 6	n = 14
	(0%)	(0%)	(28.6%)	(21.4%)	(50.0%)
Injection technique
ILESI (n = 64)	n = 0	n = 3	n = 14	n = 17	n = 30
	(0%)	(4.7%)	(21.9%)	(26.6%)	(46.9%)
TFESI (n = 56)	n = 9	n = 7	n = 20	n = 8	n = 12
	(16.1%)	(12.5%)	(35.7%)	(14.3%)	(21.4%)